(ARCHIVE) Faron Pharmaceuticals welcomes Erik Ostrowski to its Board as Non-Executive Director

– FINLAND, Turku –  Faron Pharmaceuticals Ltd (LON: FARN | First North: FARON), a clinical-stage biopharmaceutical company today announced the appointment of Erik Ostrowski to its Board as a Non-Executive Director effective immediately.

The company also announced that Matti Manner has stepped down from the Board and as Vice-Chairman of the Company.

“We are very fortunate to welcome Erik to our Board of Directors. He brings deep financial and biotech experience and will provide critical guidance as we continue to interact with the capital markets and increase our presence and investor base in the US,” said Board Chairman, Dr. Frank Armstrong.

About Erik Ostrowski

Erik Ostrowski has been AVROBIO’s CFO and Treasurer since January 2019. AVROBIO is a clinical-stage company focused on developing gene therapies to treat rare diseases. Before joining AVROBIO, Mr. Ostrowski served as CFO of Summit Therapeutics plc. (Nasdaq: SMMT) and VP of finance at Organogenesis Inc. (Nasdaq: ORGO). He previously worked in investment banking, most recently as a director with Leerink Partners LLC.

Mr. Ostrowski began his career as an accountant with Coopers & Lybrand (now PricewaterhouseCoopers) and received a B.S. in accounting and economics from Babson College and an M.B.A. from the University of Chicago Booth School of Business.

About Faron Pharmaceuticals Ltd

Faron Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs caused by dysfunction of our immune system. The Company currently has a pipeline based on the receptors involved in the regulation of immune response in oncology, organ damage, and bone marrow regeneration. Bexmarilimab, a novel anti-Clever-1 humanized antibody, is its investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid function. Currently in Phase I/II clinical development as a potential therapy for patients with untreatable solid tumors, bexmarilimab has potential as single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine is an investigational intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome and other ischemic or hyperinflammatory conditions. Traumakine is currently being evaluated in global trials as a potential treatment for hospitalized patients with COVID-19 and with the 59th Medical Wing of the US Air Force and the US Department of Defense for the prevention of multiple organ dysfunction syndromes after an ischemia-reperfusion injury caused by major trauma. Faron is headquartered in Turku, Finland with additional offices in Zürich, Switzerland, and US operations in Boston, Massachusetts.

For more information: https://www.faron.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.